




The relative strengths and weaknesses of Xeris Biopharma Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xeris Biopharma Holdings Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 11% points. The greatest weakness of Xeris Biopharma Holdings Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 137% points.

The company's Economic Capital Ratio, given in the ranking table, is 142%, being 103% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	186,818
Cost of Goods Sold	0
Intangible Assets	143,466
Liabilities, Current	73,621
Liabilities, Non-Current	9,433
Other Assets	8,722
Other Compr. Net Income	8.0
Other Expenses	32,053
Other Liabilities	216,281
Other Net Income	-14,144
Other Revenues	110,248
Property and Equipment	5,516
Research and Development	20,966
Selling, General and Administrative Expense	137,745

Output Variable	Value in 1000 USD
Assets	344,522
Liabilities	299,335
Expenses	190,764
Revenues	110,248
Stockholders Equity	45,187
Net Income	-94,660
Comprehensive Net Income	-94,656
BaseVar	479,510
ECR before LimitedLiability	1.2%
Economic Capital Ratio	142%